Drug-disease interactions: reduced beta-adrenergic and potassium channel antagonist activities of sotalol in the presence of acute and chronic inflammatory conditions in the rat

1 Inflammation may influence response to pharmacotherapy. 2 We investigated the effect of inflammation on response to sotalol, a beta -adrenergic receptor and potassium channel antagonist. Racemic sotalol (40 mg kg(-1)) was administered to healthy, acutely (interferon alpha 2a-induc ed) and chronically (Mycobacterium butyricum-induced adjuvant arthritis) in flamed male Sprague-Dawley rats (n=4-6/group). Another group of interferon- treated rats received 3 mg kg(-1) of anti-TNF antibody infliximab. Electroc ardiogram (ECG) recorded and plasma sotalol concentration monitored for 6 h . The study was repeated in acutely inflamed rats following administration of stereochemically pure individual sotalol enantiomers [40 mg kg(-1) S (po tassium channel blocker) or 20 mg kg(-1) R (beta -adrenergic/potassium chan nel blocker)]. 3 Chronic arthritis was readily evident. Acute arthritis was associated wit h elevated segmented neutrophils and increased plasma nitrite and tumour ne crosis factor (TNF) concentrations. Sotalol affected ECG in all rats. In bo th inflamed groups, however, response to sotalol in prolongation of QT inte rval (potassium channel sensitivity) was reduced. The effect of PR interval (beta -adrenergic activity) was also reduced following administration of t he racemate and R-enantiomer. No significant differences in pharmacokinetic s were observed between control and inflamed rats. 4 Infliximab reduced nitrite and TNF concentrations and reversed the effect of acute inflammation on both PR and QT intervals. 5 The reduced electrocardiographic responses to sotalol is likely due to th e influence of inflammation on the action of the drug on both beta -adrener gic and potassium channel receptors secondary to over-expression of pro-inf lammatory cytokines and/or nitric oxide. 6 Our observation may have therapeutic consequences in all conditions where inflammatory mediators are increased.